Ann Arbor, Mich-Atorvastatin, especially at higher dosages, may preventactivation of the antiplatelet agent clopidogrel, according to researchat the University of Michigan, Ann Arbor.
FDA and EMA Accepts Applications for New Nusinersen Regimen
January 23rd 2025An investigational higher dose of spinal muscular atrophy drug nusinersen gains attention as the FDA and European Medicines Agency (EMA) considerate it as an alternative than the current lower FDA-approved dosage.
Read More